Compare MLEC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | BIAF |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Cayman Islands | United States |
| Employees | N/A | 57 |
| Industry | Blank Checks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.6M |
| IPO Year | N/A | N/A |
| Metric | MLEC | BIAF |
|---|---|---|
| Price | $6.87 | $4.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 32.2K | ★ 18.6M |
| Earning Date | 04-15-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.42 | $20.95 |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $0.16 |
| 52 Week High | $23.22 | $13.50 |
| Indicator | MLEC | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 75.50 |
| Support Level | $0.60 | $0.76 |
| Resistance Level | $7.98 | $7.29 |
| Average True Range (ATR) | 1.00 | 0.75 |
| MACD | -0.55 | 0.30 |
| Stochastic Oscillator | 16.43 | 82.40 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline, such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's maximum revenues from operations in Argentina.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.